Is escitalopram appropriate for chronic functional dizziness, and what is the recommended dosing and monitoring?

Escitalopram for Chronic Functional Dizziness

Escitalopram is appropriate for chronic functional dizziness (also called persistent postural-perceptual dizziness or chronic subjective dizziness), particularly when anxiety or depressive symptoms are present, though evidence is limited to small studies.

Evidence for Use

The rationale for escitalopram in functional dizziness comes from research showing SSRIs can reduce chronic subjective dizziness. A prospective trial of sertraline (another SSRI) demonstrated that 73% of patients with chronic subjective dizziness lasting >6 months had positive responses, including those without psychiatric comorbidity 1. A smaller study specifically using escitalopram 10 mg in 12 patients with Meniere's disease and generalized anxiety disorder showed complete control of vertigo attacks 2.

The mechanism appears to involve central vestibular processing rather than peripheral vestibular pathology, as these patients have no active physical neurotologic illness but experience persistent dizziness, often with anxiety features.

Recommended Dosing

Based on FDA labeling and clinical evidence:

• Start with 10 mg once daily (morning or evening, with or without food) 33
• Increase to 20 mg after minimum 1 week if inadequate response 3
• Do not exceed 20 mg daily for most patients; citalopram/escitalopram has lower propensity for drug interactions compared to other SSRIs 44
• Use 10 mg maximum in elderly patients or those with hepatic impairment 33

The research supporting escitalopram for dizziness used 10 mg daily 2, while the sertraline study used flexible dosing up to 200 mg (median 100 mg) 1.

Monitoring Requirements

Initial Assessment

• Screen for bipolar disorder before initiating treatment (personal/family history of mania or hypomania) 33
• Obtain baseline ECG if risk factors for QT prolongation exist; citalopram/escitalopram may prolong QT interval, particularly at doses >40 mg/day 44
• Rule out active vestibular pathology through appropriate neurotologic evaluation

Ongoing Monitoring

• Assess response at 4-8 weeks: The sertraline study showed significant improvement by 16 weeks 1; the escitalopram Meniere's study showed benefit during treatment period 2
• Monitor for common adverse effects: dizziness (ironically), nausea, drowsiness, fatigue 56. In depression studies, 2.7% reported dizziness as an adverse effect 6
• Watch for serotonin syndrome if combining with other serotonergic agents (tramadol, other antidepressants, triptans, dextromethorphan) 44
• Reassess periodically for continued need, as FDA labeling emphasizes periodic re-evaluation for extended use 33

Critical Safety Considerations

Drug Interactions

• Contraindicated with MAOIs: Allow 14 days between discontinuing MAOI and starting escitalopram, and vice versa 33
• Caution with QT-prolonging drugs: Escitalopram may interact with other medications that prolong QT interval 44
• Lower interaction potential: Escitalopram has least effect on CYP450 enzymes compared to other SSRIs 44

Discontinuation

Never stop abruptly. SSRIs cause discontinuation syndrome characterized by dizziness, vertigo, imbalance, fatigue, nausea, headaches, and sensory disturbances 44. This is particularly problematic in patients being treated for dizziness, as withdrawal symptoms may mimic or worsen the original complaint.

• Taper gradually when discontinuing 33
• If intolerable symptoms occur during taper, resume previous dose and decrease more slowly 3

Clinical Algorithm

1. Confirm diagnosis: Chronic dizziness >3-6 months without active vestibular pathology
2. Screen for contraindications: Recent MAOI use, long QT syndrome, bipolar disorder risk
3. Start 10 mg daily (5 mg if elderly/hepatic impairment)
4. Assess at 1 week for tolerability
5. Increase to 20 mg at 1+ weeks if inadequate response and well-tolerated
6. Evaluate response at 8 weeks: Continue if beneficial
7. Reassess need every 3-6 months for extended treatment
8. Taper slowly when discontinuing (reduce by 5 mg every 1-2 weeks minimum)

Important Caveats

The evidence base is limited to small observational studies 21. No large randomized controlled trials specifically address escitalopram for functional dizziness. The mechanism remains unclear but likely involves central vestibular-anxiety circuits rather than peripheral vestibular pathology. This is an off-label use; FDA approval is only for major depressive disorder and generalized anxiety disorder 33.

Patients should understand that improvement may take 4-8 weeks, and that dizziness itself is a potential side effect (reported in 2.7% of patients) 6, though this typically resolves with continued treatment.